• Vaccine Name: L. major DNA Vaccine encoding Gp63
• Target Pathogen: Leishmania major
• Target Disease: Cutaneous leishmaniasis
• Vaccine Ontology ID: VO_0004046
• Type: DNA vaccine
• Status: Research
• Gp63 gene engineering:
  • Type: DNA vaccine construction
  • Description:
  • Detailed Gene Information: Click Here.
• DNA vaccine plasmid:
  • DNA vaccine plasmid name:
  • DNA vaccine plasmid VO ID: VO_0000132
• Immunization Route: Intradermal injection (i.d.)

Mouse Response

• Host Strain: BALB/c
• Vaccination Protocol: Mice were injected intradermally in the ears, foot pads, dorsal skin, or hind leg muscles with 1-100 μg of plasmid DNA diluted in PBS, freeze-thawed parasites (1.6 X 10^5) in PBS, gp63 protein (10 μg) emulsified in Freund's complete adjuvant(FCA), in FCA or PBS alone in 50 to 70- μl volumes. All
  animals were boosted at 3 weeks (Walker et al., 1998).
• Challenge Protocol: Promastigotes were subsequentiy resuspended in PBS (1 X 10^7 promastigotes/ml) and mice were infected by subcutaneous injection of 1 X 10^6 promastigotes (0.1 ml) in the dorsal side of the right foot 3 weeks after initial immunization (Walker et al., 1998).
• Efficacy: gp63-pcDNA-3 vaccination protected 30% of susceptible mice (21 of 70) from Leishmania infection (Walker et al., 1998).